XVIPF Stock - Xvivo Perfusion AB (publ)
Unlock GoAI Insights for XVIPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $822.41M | $597.54M | $415.29M | $258.39M | $179.86M |
| Gross Profit | $616.41M | $445.11M | $296.96M | $188.28M | $132.97M |
| Gross Margin | 75.0% | 74.5% | 71.5% | 72.9% | 73.9% |
| Operating Income | $88.35M | $4.19M | $6.41M | $-18,498,000 | $-45,675,000 |
| Net Income | $172.18M | $91.82M | $18.43M | $8.15M | $-43,735,000 |
| Net Margin | 20.9% | 15.4% | 4.4% | 3.2% | -24.3% |
| EPS | $5.47 | $3.07 | $0.62 | $0.28 | $-1.61 |
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Visit WebsiteEarnings History & Surprises
XVIPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | — | — | — | — |
Q4 2025 | Oct 23, 2025 | $0.05 | $0.00 | -96.6% | ✗ MISS |
Q3 2025 | Jul 11, 2025 | $0.06 | $0.01 | -92.0% | ✗ MISS |
Q2 2025 | Apr 24, 2025 | $0.08 | $-0.04 | -150.2% | ✗ MISS |
Q1 2025 | Jan 28, 2025 | $0.12 | $0.10 | -16.9% | ✗ MISS |
Q4 2024 | Oct 24, 2024 | $0.08 | $0.26 | +221.3% | ✓ BEAT |
Q3 2024 | Jul 12, 2024 | $0.06 | $0.08 | +35.7% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.04 | $0.07 | +81.9% | ✓ BEAT |
Q1 2024 | Jan 25, 2024 | $0.05 | $0.21 | +365.5% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $0.04 | $0.01 | -82.6% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.03 | $0.02 | -34.6% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $0.03 | $0.05 | +36.8% | ✓ BEAT |
Q1 2023 | Jan 26, 2023 | $0.48 | $0.27 | -43.7% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $0.20 | $0.32 | +60.0% | ✓ BEAT |
Q3 2022 | Jul 13, 2022 | $0.20 | $0.15 | -25.0% | ✗ MISS |
Q2 2022 | Apr 25, 2022 | $0.16 | $0.14 | -12.5% | ✗ MISS |
Q1 2022 | Jan 27, 2022 | $0.05 | $0.74 | +1380.0% | ✓ BEAT |
Q4 2021 | Oct 21, 2021 | $-0.03 | $-0.04 | -33.3% | ✗ MISS |
Q3 2021 | Jul 13, 2021 | $0.19 | $-0.31 | -263.2% | ✗ MISS |
Latest News
Frequently Asked Questions about XVIPF
What is XVIPF's current stock price?
What is the analyst price target for XVIPF?
What sector is Xvivo Perfusion AB (publ) in?
What is XVIPF's market cap?
Does XVIPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to XVIPF for comparison